Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Retifanlimab Combination Therapy for Endometrial Cancer
Recruiting1 awardPhase 2
Sioux Falls, South Dakota
This trial is testing retifanlimab, an immunotherapy drug, in patients with advanced endometrial cancer that has not improved with standard chemotherapy. The drug helps the immune system better identify and destroy cancer cells. It can be used alone or with other treatments.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.